South Africa and Zambia are grappling with a significant challenge in rolling out lenacapavir, a new six-monthly HIV prevention injection. Despite high demand and promising early…

South Africa accounts for over half of all lenacapavir (LEN) users in Africa, with health department data revealing 31,297 of the continent's roughly 60,000 users are in the…

For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an investigational monthly HIV prevention pill, alimatravir,…